title: Behavioral and molecular analysis of nicotine-conditioned place preference in zebrafish.
abstract: Studies using mice and rats have demonstrated that nicotine induces a conditioned place preference (CPP), with more effective results obtained by using biased procedures. Zebrafish have also been used as a model system to identify factors influencing nicotine-associated reward by using an unbiased design. Here, we report that zebrafish exhibited putative nicotine biased CPP to an initially aversive compartment (nicotine-paired group). A counterbalanced nicotine-exposed control group did not show a significant preference shift, providing evidence that the preference shift in the nicotine-paired group was not due to a reduction of aversion for this compartment. Zebrafish preference was corroborated by behavioral analysis of several indicators of drug preference, such as time spent in the drug-paired side, number of entries to the drug-paired side, and distance traveled. These results provided strong evidence that zebrafish may actually develop a preference for nicotine, although the drug was administrated in an aversive place for the fish, which was further supported by molecular studies. Reverse transcription-quantitative real-time PCR analysis depicted a significant increase in the expression of α7 and α6 but not α4 and β2 subunits of the nicotinic receptor in nicotine-paired zebrafish brains. In contrast, zebrafish brains from the counterbalanced nicotine group showed no significant changes. Moreover, CREB phosphorylation, an indicator of neural activity, accompanied the acquisition of nicotine-CPP. Our studies offered an incremental value to the drug addiction field, because they further describe behavioral features of CPP to nicotine in zebrafish. The results suggested that zebrafish exposed to nicotine in an unfriendly environment can develop a preference for that initially aversive place, which is likely due to the rewarding effect of nicotine. Therefore, this model can be used to screen exogenous and endogenous molecules involved in nicotine-associated reward in vertebrates.
authors.affiliation: Departamento de Fisiología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.
authors.forename: Ximena
authors.initials: X
authors.lastname: Kedikian
authors.forename: Maria Paula
authors.initials: MP
authors.lastname: Faillace
authors.forename: Ramón
authors.initials: R
authors.lastname: Bernabeu
mesh_terms: D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D003213:Conditioning, Psychological / Q000502:physiology*; D017362:Cyclic AMP Response Element-Binding Protein / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D009538:Nicotine / Q000494:pharmacology*; D060888:Real-Time Polymerase Chain Reaction; D011978:Receptors, Nicotinic / Q000235:genetics / Q000378:metabolism; D015027:Zebrafish / Q000502:physiology*; D029961:Zebrafish Proteins / Q000235:genetics / Q000378:metabolism
chemical_list: D017362:Cyclic AMP Response Element-Binding Protein; D011978:Receptors, Nicotinic; D029961:Zebrafish Proteins; D009538:Nicotine
references.citation: J Neurochem. 2011 Feb;116(4):636-45
references.pmid: 21166804
references.citation: J Exp Biol. 2008 May;211(Pt 10):1623-34
references.pmid: 18456890
references.citation: Genes Brain Behav. 2006 Oct;5(7):497-505
references.pmid: 17010096
references.citation: Psychopharmacology (Berl). 2009 Nov;207(1):57-71
references.pmid: 19711055
references.citation: Pharmacol Biochem Behav. 2000 Dec;67(4):773-82
references.pmid: 11166068
references.citation: Neuroscience. 2007 May 25;146(3):1109-16
references.pmid: 17428610
references.citation: Genome Biol. 2009;10(7):R81
references.pmid: 19646228
references.citation: J Mol Med (Berl). 2006 Nov;84(11):901-10
references.pmid: 16972087
references.citation: Behav Brain Res. 2011 Feb 2;217(1):128-33
references.pmid: 20974186
references.citation: Pharmacol Biochem Behav. 2008 Mar;89(1):94-100
references.pmid: 18086490
references.citation: Neuron. 2011 Apr 14;70(1):20-33
references.pmid: 21482353
references.citation: Prog Neurobiol. 1998 Dec;56(6):613-72
references.pmid: 9871940
references.citation: Trends Neurosci. 2005 Jul;28(7):371-8
references.pmid: 15979501
references.citation: Psychopharmacology (Berl). 2013 Apr;226(3):551-60
references.pmid: 23192315
references.citation: Neurobiol Learn Mem. 2007 Jan;87(1):72-7
references.pmid: 16861014
references.citation: Handb Exp Pharmacol. 2009;(192):173-207
references.pmid: 19184650
references.citation: Nature. 2011 Mar 31;471(7340):597-601
references.pmid: 21278726
references.citation: Philos Trans R Soc Lond B Biol Sci. 2008 Oct 12;363(1507):3137-46
references.pmid: 18640920
references.citation: Genes Brain Behav. 2004 Apr;3(2):63-74
references.pmid: 15005714
references.citation: Trends Pharmacol Sci. 1990 Jun;11(6):216-9
references.pmid: 2200178
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 1994 Sep;18(5):925-33
references.pmid: 7972862
references.citation: J Neurobiol. 2003 Jan;54(1):161-78
references.pmid: 12486703
references.citation: Neuron. 2008 Oct 9;60(1):123-36
references.pmid: 18940593
references.citation: Nat Rev Neurosci. 2010 Jun;11(6):389-401
references.pmid: 20485364
references.citation: Nat Protoc. 2011 Mar;6(3):338-45
references.pmid: 21372814
references.citation: Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11691-6
references.pmid: 11553778
references.citation: Behav Brain Res. 2009 Dec 14;205(1):38-44
references.pmid: 19540270
references.citation: Neuron. 2002 Mar 14;33(6):905-19
references.pmid: 11906697
references.citation: Methods. 2006 Jul;39(3):262-74
references.pmid: 16809048
references.citation: Neuropharmacology. 2006 Jan;50(1):36-46
references.pmid: 16153666
references.citation: Hum Genet. 2012 Jun;131(6):977-1008
references.pmid: 22207143
references.citation: Annu Rev Neurosci. 2007;30:259-88
references.pmid: 17600522
references.citation: Psychopharmacology (Berl). 2006 Mar;184(3-4):339-44
references.pmid: 16416156
references.citation: Biochem Pharmacol. 2012 Aug 1;84(3):352-65
references.pmid: 22580045
references.citation: Pharmacol Biochem Behav. 2011 Sep;99(3):519-23
references.pmid: 21600911
references.citation: Nat Protoc. 2010 Nov;5(11):1786-99
references.pmid: 21030954
references.citation: J Pharmacol Exp Ther. 1996 Jul;278(1):361-9
references.pmid: 8764371
references.citation: Psychopharmacology (Berl). 2005 Apr;178(4):481-92
references.pmid: 15765262
references.citation: Nat Rev Neurosci. 2001 Feb;2(2):119-28
references.pmid: 11252991
references.citation: Brain Res Brain Res Rev. 2005 Jun;48(3):420-37
references.pmid: 15914250
references.citation: J Neurosci. 1992 Jul;12(7):2765-84
references.pmid: 1613557
references.citation: Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):7041-6
references.pmid: 9192688
references.citation: Brain Res. 2001 Jan 19;889(1-2):316-30
references.pmid: 11166725
references.citation: Neuroreport. 2001 Mar 5;12(3):569-72
references.pmid: 11234765
references.citation: Nicotine Tob Res. 2011 May;13(5):301-12
references.pmid: 21385906
references.citation: Trends Neurosci. 2005 Aug;28(8):436-45
references.pmid: 15982754
references.citation: Curr Drug Targets CNS Neurol Disord. 2002 Aug;1(4):359-85
references.pmid: 12769610
references.citation: Nat Neurosci. 2010 Nov;13(11):1354-6
references.pmid: 20935642
references.citation: Psychopharmacology (Berl). 2012 Mar;220(1):1-14
references.pmid: 21901321
references.citation: Science. 1983 Apr 8;220(4593):214-6
references.pmid: 6828889
references.citation: Neuropsychopharmacology. 2009 Jul;34(8):1993-2001
references.pmid: 19212318
references.citation: Brain Res Brain Res Rev. 1993 Sep-Dec;18(3):247-91
references.pmid: 8401595
references.citation: PLoS One. 2011 Mar 07;6(3):e17597
references.pmid: 21408171
references.citation: Cell. 2006 Nov 3;127(3):621-33
references.pmid: 17081982
references.citation: Rev Neurosci. 2011;22(1):37-48
references.pmid: 21615260